Intercept Pharmaceuticals' Above $300 -- More Mega Millions On The Way?

Jan 17 2014, 1:53pm CST | by

Anyone following the stock of Intercept Pharmaceuticals (NASDAQ:ICPT) closely cannot help but get dizzy. After racing from $72 to $497 last week, the stock corrected sharply this week–trading below $250 early in the week, before recovering nicely to above $300 in the last two days.

Does this mean that the correction is over? Are more mega millions on the way for the company’s shareholders?

We cannot say. What we can say is that this is a highly speculative stock for investors who have faith in the company’s prospects.

Intercept Pharmaceuticals develops innovative treatment for chronic diseases likeobeticholic acid, a bile acid analog (OCA), which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea.

That certainly sounds like a very promising compound, and last week it performed unexpectedly well in a clinical trial, sending the company’s stock soaring — as this development makes it very likely that the compound will receive FDA approval.

As one of commentators observed in a previous piece:

“People bid up stock for market potential. Stock trading is speculative in nature and nothing is pure black and white in the Bio-tech world. I think you need to understand some fundamentals of the statistics and clinical trials before you can comment on the likelihood of FDA approval. Currently, what investors perceived is based on 5% type I error rate. The actual error rate is much much smaller than 5%, given the fact that the phase II clinical trial was stopped much earlier than designed.”

Even so, before rushing to buy the stock at these levels, investors should understand three things:

First, we are still talking about a drug that is very likely to win FDA approval, not a drug that has already received approval.

Second, even if OCA passes the FDA test, it must subsequently pass the market test. Investors have to look no further than the fate of Dendreon’s drug PROVENGE and Affymax’s drug OMONTYS, neither of which performed well in market tests.

Third, even if OCA passes both the FDA and the market test, at the current market valuation, the company is valued close to 7 percent of the value of Amgen Inc., which has been around for more than three decades and has several blockbuster stocks in the market.

A valuation such as this makes Intercept Pharmaceuticals hardly a bargain, even if it successfully passes the FDA and the market test. That’s why I’ll still stay away from the stock.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Global entrepreneurship summit boost for SMEs
Marrakech, Nov 22 (IANS) Nine agreements were signed between the Moroccan General Confederation of Enterprises (CGEM) and several small and medium enterprises (SMEs) as well as between major Moroccan banks and start-ups at the 5th Global Entrepreneurship Summit (GES 2014) held in Morocco.
 
 
NASA's flying saucer among 'Best of What's New'
Washington, Nov 22 (IANS) NASA's Low-Density Supersonic Decelerator (LDSD), a spacecraft that aims to facilitate the safe landing of future Mars missions, has earned a place in the the Popular Science magazine's "Best Of What's New" list.
 
 
Indian helping to light up Gambia (Diaspora Feature)
Banjul (Gambia), Nov 22 (IANS) Like many Indians who are proving to be philanthropists around Africa, Ram Mohan has set up a social business called Comafrique Intelizon Initiative and has embarked on the replacement of candles in villages in the Gambia with solar lights from India.
 
 
Leopards in human areas not conflict animals: Study
New Delhi, Nov 22 (IANS) Leopards in human areas are not always "stray" or "conflict" animals but residents with strategies to thrive in human dominated areas, says the first GPS-based study of leopards in India.
 
 
 

Latest from the Network

Davis Cup final: Switzerland nudges ahead with doubles win
Lille, Nov 23 (IANS/EFE) Superstar Swiss duo of Roger Federer and Stanislas Wawrinka put their country ahead in the Davis Cup final with a 6-3, 7-5, 6-4 victory over the French pair of Richard Gasquet and Julien...
Read more on Sport Balla
 
Former police official arrested over students' disappearance in Mexico
Mexico City, Nov 23 (IANS/EFE) A former deputy police chief and suspected member of the Guerreros Unidos ("United Warriors") drug cartel, that allegedly, is involved in the disappearance of 43 students in Mexico...
Read more on Politics Balla
 
Iran to allow UN inspectors access to Marivan nuclear site
Tehran, Nov 23 (IANS) Iran decided to allow UN nuclear inspectors access to its Marivan nuclear site, Atomic Energy Organisation of Iran (AEOI) said Saturday. "We are ready to provide a controlled access to the...
Read more on Politics Balla
 
Kendall Jenner feels she is like Hannah Montana
Los Angeles, Nov 23 (IANS) Model Kendall Jenner, who is seen in a reality TV show "Kourtney and Khloé Take The Hamptons", says she feels "like Hannah Montana" while juggling between fashion and TV. Hannah Montana,...
Read more on Celebrity Balla
 
Iran nuclear issue: Kerry holds talks with Gulf foreign ministers
Vienna, Nov 23 (IANS) US Secretary of State John Kerry held talks with the foreign ministers of UAE, Kuwait, Qatar and Bahrain on the Iranian nuclear issue Saturday. Earlier, Kerry delayed his departure from Vienna in...
Read more on Politics Balla
 
Professor Green not ready for kids
Professor Green and Millie Mackintosh are not ready to have children. The 30-year-old rapper - who is married to the former 'Made in Chelsea' star - has revealed they do not want to have a baby yet because their dogs...
Read more on Celebrity Balla
 
Taylor Swift's midriff mystery
Taylor Swift doesn't want people to know she has a belly button. The 'Blank Space' hitmaker admitted she chooses not to wear tops which reveal her midriff because she wants to keep her fans guessing as to whether she...
Read more on Celebrity Balla
 
Wilko Johnson: 'I shouldn't be here'
Wilko Johnson believes he ''shouldn't be here'' after battling cancer. The 'Game of Thrones' actor was given the all clear in October following a 17-month battle with pancreatic cancer, and has recalled the ''marvellous...
Read more on Celebrity Balla
 
Penelope Cruz joins Ben Stiller in 'Zoolander 2'
Los Angeles, Nov 23 (IANS) Actress Penelope Cruz is all set to star with actor Ben Stiller in the film "Zoolander 2". According to Deadline magazine, details of Cruz's role in the sequel of "Zoolander" has not been...
Read more on Celebrity Balla
 
No general election in Pakistan before 2018: Nawaz Sharif
Islamabad, Nov 23 (IANS) Pakistan Prime Minister Nawaz Sharif said Saturday that a general election would not be held in the country before 2018. He thus rejected the demands by the opposition Pakistan Tehreek-i-Insaf...
Read more on Politics Balla